IN2012DN00764A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00764A
IN2012DN00764A IN764DEN2012A IN2012DN00764A IN 2012DN00764 A IN2012DN00764 A IN 2012DN00764A IN 764DEN2012 A IN764DEN2012 A IN 764DEN2012A IN 2012DN00764 A IN2012DN00764 A IN 2012DN00764A
Authority
IN
India
Prior art keywords
receptor
compounds
medicaments
antagonists
concerned
Prior art date
Application number
Inventor
Johannes Aebi
Alfred Binggeli
Luke Green
Guido Hartmann
Hans P Maerki
Patrizio Mattei
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN00764A publication Critical patent/IN2012DN00764A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention is concerned with novel bicyclic compounds of formula (I) wherein A, L, E, F, G, R1, R2, R3, R4, R5, R6, R7, V, W and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
IN764DEN2012 2009-10-07 2010-10-05 IN2012DN00764A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172408 2009-10-07
PCT/EP2010/064770 WO2011042399A1 (en) 2009-10-07 2010-10-05 Bicyclic heterocycles and their use as ccr2 receptor antagonists

Publications (1)

Publication Number Publication Date
IN2012DN00764A true IN2012DN00764A (en) 2015-06-26

Family

ID=43105073

Family Applications (1)

Application Number Title Priority Date Filing Date
IN764DEN2012 IN2012DN00764A (en) 2009-10-07 2010-10-05

Country Status (13)

Country Link
US (1) US8471004B2 (en)
EP (1) EP2486042B1 (en)
JP (1) JP5559336B2 (en)
KR (1) KR101451487B1 (en)
CN (1) CN102574858B (en)
AU (1) AU2010305495A1 (en)
BR (1) BR112012008221A2 (en)
CA (1) CA2774215A1 (en)
ES (1) ES2455266T3 (en)
IL (1) IL217965A0 (en)
IN (1) IN2012DN00764A (en)
MX (1) MX2012002390A (en)
WO (1) WO2011042399A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
DK3050574T3 (en) 2015-01-28 2020-01-20 Univ Bordeaux Use of plerixafor for the treatment and / or prevention of acute exacerbations of chronic obstructive pulmonary disease
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN111423454B (en) * 2020-04-24 2021-06-22 苏州大学 Piperazine compound and application thereof in preparing chemokine receptor CCR2 antagonist
CN113979889A (en) * 2021-11-09 2022-01-28 西安康福诺生物科技有限公司 Synthesis method of bifunctional polyethylene glycol amine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740256A1 (en) 1987-05-14 1988-12-08 Bayer Ag THIAZOLO-HYDANTOINE
WO2002070523A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
WO2004076411A2 (en) * 2003-02-24 2004-09-10 Merck & Co., Inc. Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
DE602005010577D1 (en) * 2004-05-26 2008-12-04 Janssen Pharmaceutica Nv MERCAPTOIMIDAZOLE AS CCR2 RECEPTOR ANTAGONISTS
JP2008531714A (en) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition for the treatment and / or prevention of anxiety disorders
BRPI0710512A2 (en) * 2006-04-20 2012-06-05 Hoffmann La Roche diazepan-derived modulators of chemokine receptors
AU2008277796A1 (en) 2007-07-19 2009-01-22 F. Hoffmann-La Roche Ag Novel heterocyclyl compounds and their use as chemokine antagonists
BRPI0817935A2 (en) 2007-10-01 2015-04-07 Hoffmann La Roche BIARILLE DERIVATIVES

Also Published As

Publication number Publication date
BR112012008221A2 (en) 2016-03-08
EP2486042A1 (en) 2012-08-15
CN102574858A (en) 2012-07-11
KR20120051090A (en) 2012-05-21
JP5559336B2 (en) 2014-07-23
WO2011042399A1 (en) 2011-04-14
KR101451487B1 (en) 2014-10-15
JP2013506701A (en) 2013-02-28
US20110082294A1 (en) 2011-04-07
IL217965A0 (en) 2012-03-29
CN102574858B (en) 2015-06-24
AU2010305495A1 (en) 2012-03-15
US8471004B2 (en) 2013-06-25
EP2486042B1 (en) 2014-01-22
MX2012002390A (en) 2012-04-02
ES2455266T3 (en) 2014-04-15
CA2774215A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
WO2009010429A3 (en) Novel heterocyclyl compounds and their use as chemokine antagonists
MX2009009690A (en) Thiazolidine derivatives as orexin receptor antagonists.
GEP20146124B (en) Novel ccr2 receptor antagonists and usage thereof
MX2009014002A (en) Imidazole derivatives as ccr2 receptor antagonists.
TW200738655A (en) Novel bicyclic sulfonamide derivatives
TW200745032A (en) Novel heterobicyclic derivatives
IN2012DN03045A (en)
ATE524466T1 (en) 3-AZABICYCLOÄ3.3.0ÜOCTANE COMPOUNDS
MX2010003621A (en) New biaryl derivatives.
DE602008002934D1 (en) 2-CYCLOPROPYLTHIAZOLDERIVATE
MX2010008993A (en) 2-aza-bicyclo[2.2.1]heptane derivatives.
WO2009013211A3 (en) New pyrazol derivatives
PE20120693A1 (en) HETEROCYCLES COMPOUNDS AS MODULATORS OF PYRUVATE KINASE M2 (PKM2)
PE20121050A1 (en) N- (1- (4- (1H-PYRAZOLE-5-IL) FTALAZIN-1-IL) PIPERIDIN-4-IL) -BENZAMIDE COMPOUNDS SUBSTITUTE AS ANTAGONISTS IN THE HEDGEHOG TRAJECTORY
MX2011011854A (en) Dihydropyrimidinones for use as bace2 inhibitors.
MX2010001575A (en) 1,2-diamido-ethylene derivatives as orexin antagonists.
GEP20125590B (en) Benzazepine derivatives and usage thereof as histamine h3 antagonists
RS20090208A (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
MX2010002760A (en) Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists.
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
IL206359A0 (en) Sulfonamides as orexin antagonists
MX2012003469A (en) Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors.
PH12014501540A1 (en) 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives
MX2009003645A (en) N-substituted-azacyclylamines as histamine-3 antagonists.
IL201317A0 (en) Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists